Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CP101
Finch Therapeutics Group
Clostridium Difficile Infection
1 trial -
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Jazz Pharmaceuticals Ireland Limited
Colorectal Neoplasms
1 trial -
CRD-4730, Encapsulation of microcrystalline cellulose into HPMC capsules to match the CRD-4730 active capsules in appearance
Lacuna Pharma Pty Ltd
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
1 trial -
CTI-1601
Larimar Therapeutics
Friedreich Ataxia
4 trials -
CYSTAGON 150 mg hard capsules
The George Institute
Infectious diseases of respiratory system (COVID-19)
1 trial -
Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788
Ningbo Cancer Hospital
Metastatic castration-resistant prostate cancer
1 trial -
Calcium Folinate 10 mg/ml Solution for injection or infusion, Irinotecanhydrochloridetrihydraat Hikma 20 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Avastin 25 mg/ml concentrate for solution for infusion., Oxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie
Disc Medicine
Patients with colorectal peritoneal metastases with a PCI-score of 1-20
1 trial -
Carbon Nanoparticle Iron Suspension for Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HNSCC
1 trial -
Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent
Hoffmann-La Roche
Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Cefiderocol
Shionogi B.V.
Gram-negative Bacterial Infections
1 trial -
Ceftriaxone 1000mg + doxycycline 100 mg
Hong Kong Baptist University
Neisseria Gonorrhoeae Infection
1 trial -
Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
Lxo Ireland Designated Activity Company
Liver Transplant Rejection
1 trial -
Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial
Pari Pharma GmbH
Inclusion Body Myositis
1 trial -
Cemiplimab
Regeneron UK Limited
HIV Infections
1 trial -
ChAdOx1-HPV
Barinthus Biotherapeutics plc.
HPV Infection
1 trial -
Chinese herbal concoction twice a day for 6 months
Universal Integrated
Myelodysplastic Syndrome (MDS)
1 trial -
Chlorid sodný B. Braun 0,9 % infuzní roztok, DUOFAG
Lacuna Pharma Pty Ltd
Surgical wound infection/dehiscence caused by S. aureus and/or P. aeruginosa colonization
1 trial -
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer
The George Institute
Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.
1 trial -
Cinryze 500 IU powder and solvent for solution for injection, Saline Solution Basi 9 mg/ml solution for infusion
Disc Medicine
Traumatic Brain Injury
1 trial -
Colon originated: Neostigmin, Colonoscopy decompression, Surgery
Chinese University of Hong Kong
Acute Lower Gastrointestinal Dysfunction
1 trial -
Combination of MK3475 with Metronomic CP
Lxo Ireland Designated Activity Company
Sarcoma
1 trial -
Comirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, LVT-001
Tour Hekla
Healthy volunteers
1 trial -
Computerized cognitively stimulating activities
BRIGHT MINDS BIOSCIENCES INC.
Substance Use Disorders
1 trial -
Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.
Lxo Ireland Designated Activity Company
Graft Versus Host Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources